Skip to content

Influence of midazolam on postoperative delirium in elderly patients undergoing joint replacement: a multicenter , double-blind, randomized, controlled clinical trial

Influence of midazolam on postoperative delirium in elderly patients undergoing joint replacement: a multicenter , double-blind, randomized, controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072421
Enrollment
Unknown
Registered
2023-06-13
Start date
2023-06-14
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative delirium

Interventions

intervention group:midazolam
control group:normal saline

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1)Patients undergoing elective surgery for joint replacement under general anesthesia;2)Age=60 years;3)American Association of Anesthesiologists Classification (ASA):?~? grades.

Exclusion criteria

Exclusion criteria: 1)Patients with a history of neurological diseases; 2)Patients with a history of neurosurgery;3)Patients with a history of mental illness, such as schizophrenia; 4)Received antipsychotic medication within 30 days prior to enrollment in the study; 5)Inability to communicate properly for any reason; 6)Patients who are already allergic to benzodiazepines; 7)Angle-closure glaucoma patients; 8)Those who participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium;

Secondary

MeasureTime frame
The severity of postoperative delirium;Assessment of daily living ability;Pain score;Recovery quality;Postoperative complications;All-cause mortality during hospitalization;Sleep quality;

Countries

China

Contacts

Public ContactJing Yang

West China Hospital of Sichuan University

hxyangjing@qq.com+86 189 8060 2269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026